Literature DB >> 12187937

Correlation of simultaneous differential gene expression in the blood and heart with known mechanisms of adriamycin-induced cardiomyopathy in the rat.

H Roger Brown1, Hong Ni, Gina Benavides, Lawrence Yoon, Karim Hyder, Jaisri Giridhar, Guy Gardner, Ronald D Tyler, Kevin T Morgan.   

Abstract

As the genomes of mammalian species become sequenced and gene functions are ascribed, the use of differential gene expression (DGE) to evaluate organ function will become common in the experimental evaluation of new drug therapies. The ability to translate this technology into useful information for human exposures depends on tissue sampling that is impractical or generally not possible in man. The possibility that the DGE of nucleated cells, reticulocytes, or platelets in blood may present the necessary link with target organ toxicity provides an opportunity to correlate preclinical with clinical outcomes. Adriamycin is highly effective alone and more frequently in combination with other chemotherapeutic agents in the treatment of a variety of susceptible malignancies. Adriamycin-induced cardiomyopathy was examined as an endpoint to measure the utility of DOE on whole blood as a predictor of cardiac toxicity. Statistically significant gene changes were observed between relevant blood and cardiac gene profiles that corroborated the accepted mechanisms of toxicity (oxidative stress, effects on carnitine transport, DNA intercalation). There were, however, clear indications that other target organs (bone marrow and intestinal tract) were affected. The divergent expression of some genes between the blood and the heart on day 7 may also indicate the timing and mechanism of development of the cardiomyopathy and confirm current therapeutic approaches for its prevention. The data demonstrate that whole blood gene expression particularly in relation to oxidative stress, in conjunction with standard hematology and clinical chemistry, may be useful in monitoring and predicting cardiac damage secondary to adriamycin administration. Appendices A & B, referenced in this paper, are not printed in this issue of Toxicologic Pathology. They are available as downloadable text files at http://taylorandfrancis.metapress.com/openurl.asp?genre=journal&issn=0192-6233. To access them, click on the issue link for 30(4), then select this article. A download option appears at the bottom of this abstract. In order to access the full article online, you must either have an individual subscription or a member subscription accessed through www.toxpath.org.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12187937     DOI: 10.1080/01926230290105604

Source DB:  PubMed          Journal:  Toxicol Pathol        ISSN: 0192-6233            Impact factor:   1.902


  8 in total

1.  Do blood cells mimic gene expression profile alterations known to occur in muscular adaptation to endurance training?

Authors:  J Zeibig; H Karlic; A Lohninger; R Damsgaard; R Dumsgaard; G Smekal
Journal:  Eur J Appl Physiol       Date:  2005-04-07       Impact factor: 3.078

2.  Effects of doxorubicin-containing chemotherapy and a combination with L-carnitine on oxidative metabolism in patients with non-Hodgkin lymphoma.

Authors:  Raimund Waldner; Claudia Laschan; Alfred Lohninger; Martin Gessner; Heinz Tüchler; Marlies Huemer; Wolfgang Spiegel; Heidrun Karlic
Journal:  J Cancer Res Clin Oncol       Date:  2005-11-08       Impact factor: 4.553

Review 3.  Genomics, transcriptional profiling, and heart failure.

Authors:  Kenneth B Margulies; Daniel P Bednarik; Daniel L Dries
Journal:  J Am Coll Cardiol       Date:  2009-05-12       Impact factor: 24.094

4.  Phenylbutyrate, a histone deacetylase inhibitor, protects against Adriamycin-induced cardiac injury.

Authors:  Chotiros Daosukho; Yumin Chen; Teresa Noel; Pradoldej Sompol; Ramaneeya Nithipongvanitch; Joyce M Velez; Terry D Oberley; Daret K St Clair
Journal:  Free Radic Biol Med       Date:  2007-03-12       Impact factor: 7.376

5.  Effect of intermittent hypoxic training on HIF gene expression in human skeletal muscle and leukocytes.

Authors:  Rémi Mounier; Vincent Pialoux; Belle Roels; Claire Thomas; Grégoire Millet; Jacques Mercier; Jean Coudert; Nicole Fellmann; Eric Clottes
Journal:  Eur J Appl Physiol       Date:  2008-11-19       Impact factor: 3.078

6.  Successful drug development despite adverse preclinical findings part 1: processes to address issues and most important findings.

Authors:  Robert A Ettlin; Junji Kuroda; Stephanie Plassmann; David E Prentice
Journal:  J Toxicol Pathol       Date:  2010-12-16       Impact factor: 1.628

7.  Meeting report: Validation of toxicogenomics-based test systems: ECVAM-ICCVAM/NICEATM considerations for regulatory use.

Authors:  Raffaella Corvi; Hans-Jürgen Ahr; Silvio Albertini; David H Blakey; Libero Clerici; Sandra Coecke; George R Douglas; Laura Gribaldo; John P Groten; Bernd Haase; Karen Hamernik; Thomas Hartung; Tohru Inoue; Ian Indans; Daniela Maurici; George Orphanides; Diana Rembges; Susanna-Assunta Sansone; Jason R Snape; Eisaku Toda; Weida Tong; Joost H van Delft; Brenda Weis; Leonard M Schechtman
Journal:  Environ Health Perspect       Date:  2006-03       Impact factor: 9.031

Review 8.  Integrative Therapies and Cardiovascular Disease in the Breast Cancer Population: A Review, Part 1.

Authors:  Khara Lucius; Kristen Trukova
Journal:  Integr Med (Encinitas)       Date:  2015-08
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.